As part of our continued efforts to foster strong partnerships across the global health ecosystem, DCVMN CEO, Rajinder Suri met with leadership from key institutions in China, including PATH, the Gates Foundation, and the Council for the Promotion of International Vaccine Cooperation (CPIVC) of the China Association for Vaccines (CAV).
These meaningful conversations explored how DCVMN and our partners can jointly advocate for greater investment in developing country vaccine manufacturers, while also identifying opportunities for collaboration, particularly in connecting Chinese and African manufacturers to address supply gaps and support vaccine equity.
Mr. Suri shared updates on the vaccine pipelines of DCVMN members in China and beyond, opening the door for deeper engagement around product development, regulatory support and regional manufacturing partnerships. Regulatory harmonization between developing countries was also a key topic of discussion, with all parties recognizing the importance of streamlined pathways to accelerate access.
DCVMN was also pleased to engage directly with the China Association for Vaccines (CAV), learning more about their pivotal role in bridging China’s vaccine industry and the Government. With China standing as one of the few countries capable of meeting national vaccine demand largely through domestic manufacturing, the insights from these discussions will be shared across our network of manufacturers spanning 17 countries.
A highlight of the visit was the meeting with Professor George Gao, former Director of the China CDC, where discussions turned toward the future of vaccines and the role of AI in vaccine design, from structure-based approaches and viral entry modeling to immune response prediction and pandemic preparedness.
DCVMN remains committed to working alongside our global partners to strengthen the vaccine manufacturing ecosystem and support innovation to ensure no region is left behind in the journey toward vaccine equity.
